Monoclonal antibodies continue their march on the markets, optimized so-called biobetter versions of existing biologics are also gaining ground, but the rate of biosimilar approvals has seen a dramatic slowdown in recent years.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Walsh, G. Biopharmaceutical benchmarks. Nat. Biotechnol. 24, 769–776 (2006).
Walsh, G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28, 917–924 (2010).
Blackstone, E. & Fuhr, J. The Economics of biosimilars. American Health and Drug Benefits (July 2, 2014).
Rickwoood, S. & Di Biase, S. Searching for Terra Firma in the Biosimilars and Non-Original Biologics Market (IMS Health, Parsippany, NJ, USA, 2013).
Hospira Reports on success of its biosimilar proteins in Europe and Australia, La Meire Biologics 6, 3–4 (2013).
Dalgaard, K. et al. Biosimilars Seven Years On: Where are We and What's Next? (McKinsey and Company, New York, NY, USA, 2013).
Perez, H.L. et al. Antibody–drug conjugates: current status and future directions. Drug Discov. Today 19, 869–881 (2014).
Goede, V. et al. Comparison of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb in Patients with Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results of the CLL11 Trial. Presented at the 55th ASH Annual Meeting and Exposition. New Orleans, LA. December 7-10, 2013. Abstract 6.
Nielsen, L.S. et al. Single-batch production of recombinant human polyclonal antibodies. Mol. Biotechnol. 45, 257–266 (2010).
Kling, J. Sanofi to propel inhaled insulin Afrezza to market. Nat. Biotechnol. 32, 851–852 (2014).
Kwon, K.C. et al. Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv. Drug Deliv. Rev. 65, 782–799 (2013).
Emerton, D.A. Profitability in the biosimilars market: can you translate scientific excellence into a healthy commercial return? Bioprocess Int. 11, 6–14 (2013).
Brennan, T.A. & Wilson, J.M. The special case of gene therapy pricing. Nat. Biotechnol. 32, 874–876 (2014).
PhRMA. Medicines in Development: Biologics. 2013 report. http://www.phrma.org/sites/default/files/pdf/biologics2013.pdf (PhRMA, Washington, DC, 2013)
Olinger, G.G. et al. Delay treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus monkeys. Proc. Natl. Acad. Sci. USA 109, 18030–18035 (2012).
Qui, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 10.1038/nature13777 (29 August 2014).
Broz, A., Huang, N. & Unruh, G. Plant-based protein biomanufacturing. Genet. Eng. Biotechnol. News 33, 32–33 (2013).
Beck, A. & Reichert, J.M. Approval of the first biosimilar antibodies in Europe. MAbs 5, 621–623 (2013).
The author declares no competing financial interests.
About this article
Investigating the influence of physiologically relevant hydrostatic pressure on CHO cell batch culture
Scientific Reports (2021)
Integrating research into a molecular cloning course to address the evolving biotechnology landscape
Biochemistry and Molecular Biology Education (2021)
Middle-up characterization of monoclonal antibodies by online reduction liquid chromatography-mass spectrometry
Journal of Chromatography A (2021)
Recent advances in systems and synthetic biology approaches for developing novel cell-factories in non-conventional yeasts
Biotechnology Advances (2021)
Biodistribution and elimination pathways of PEGylated recombinant human deoxyribonuclease I after pulmonary delivery in mice
Journal of Controlled Release (2021)